Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/a3/8d/e8/a38de8ef-12fa-b062-a68f-7ed4fa9380f0/mza_4291354867745059753.jpg/600x600bb.jpg
Inside Matters
Dr James McIlroy
67 episodes
4 days ago
Conversations with the brightest, most forward-thinking minds in health, fitness, science, nutrition and business. In-depth discussions about how our gut microbiome impacts our health, well-being, mood and much more.
Show more...
Nutrition
Health & Fitness,
Fitness
RSS
All content for Inside Matters is the property of Dr James McIlroy and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Conversations with the brightest, most forward-thinking minds in health, fitness, science, nutrition and business. In-depth discussions about how our gut microbiome impacts our health, well-being, mood and much more.
Show more...
Nutrition
Health & Fitness,
Fitness
https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog5262177/BIOME_BITES_16_PODCAST_ALBUM_ART_updated8cank.jpg
Why I’m Excited About EnteroBiotix
Inside Matters
15 minutes 54 seconds
10 months ago
Why I’m Excited About EnteroBiotix
In this episode, James discusses the progress and future of EnteroBiotix, a company focused on gut health and microbiome therapeutics. He reflects on the transformative year of 2024, highlighting significant milestones in clinical trials, particularly in liver disease and irritable bowel syndrome (IBS). James emphasises the importance of clinical data in drug development and the company's commitment to improving patient care through innovative therapies. He also shares insights on the connection between gut health and overall well-being, and the company's plans for future growth and regulatory engagement.   Takeaways: EnteroBiotix aims to improve gut health and microbiome therapeutics. 2024 was a transformative year with significant milestones. Clinical trials are crucial for proving drug efficacy. The connection between gut health and liver disease is significant. Irritable Bowel Syndrome (IBS) is often misunderstood as a syndrome. EnteroBiotix is focused on full-spectrum microbiome therapy. Data from clinical trials is essential for stakeholder engagement. The company is committed to patient care and innovative solutions. Regulatory engagement is key for future drug development. The team at Interbiotics is dedicated and capable, of achieving remarkable results. Timestamps: 00:00 Welcome and Introduction 00:19 Overview of EnteroBiotix 01:13 Reflecting on 2024 Achievements 02:00 Clinical Trials and Milestones 04:16 Liver Cirrhosis Trial Insights 08:07 IBS Clinical Trial Success 11:52 Future Prospects and Goals 14:45 Conclusion and Gut Health Tips
Inside Matters
Conversations with the brightest, most forward-thinking minds in health, fitness, science, nutrition and business. In-depth discussions about how our gut microbiome impacts our health, well-being, mood and much more.